NCT02731352View on ClinicalTrials.gov

Study of Apatinib in Patients With Differentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 11, 2016

Primary Completion Date

February 27, 2020

Study Completion Date

February 28, 2021

Conditions
Thyroid Cancer
Interventions
DRUG

Apatinib

Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.

DRUG

Apatinib

Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT02731352 - Study of Apatinib in Patients With Differentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter